A trial of finerenone in a patient with primary aldosteronism

Primary aldosteronism (PA), a common secondary cause of arterial hypertension, is treated either surgicaly, or pharmacologically with mineralocorticoid receptor antagonists (MRA). These drugs, while effective, can cause allergic reactions and have side-effects, including menstrual cycle disorders in women. Finerenone is a new, highly selective, nonsteroidal MRA with excellent side-effect profile, primarily intended to slow the progression of diabetic kidney disease and improve cardiovascular outcomes in these patients. No data are available data so far on its effect on patients with PA.